Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Incannex Healthcare Limited

Incannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A

Benzinga · Jul 21, 2022

Incannex Reveals Clinical Trial Results On Dronabinol-Based Drug For Obstructive Sleep Apnea

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, has completed an analysis of data from the Phase 2 proof-of-concept clinical trial invest

Benzinga · Jun 3, 2022

Incannex Healthcare To Acquire APIRx Pharmaceuticals For $93.3M

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) announced that it has executed a term sheet with binding commercial terms to wholly acquire APIRx Pharmaceutical USA, LLC, subject to shareholder approval under ASX listing Rule 7.1.

Benzinga · Mar 24, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Incannex's Cannabinoid Combo Product Reduces AHI In Sleep Apnea Patients

Incannex Healthcare Limited (NASDAQ: IXHL) has

Benzinga · Mar 10, 2022

Incannex Clinical Trial Shows Notable Reduction In The Apnoea Hypopnoea Index With Novel Cannabinoid Product

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL),a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, has completed of a preliminary analysis of data from its phase 2, proof-of-concept cl

Benzinga · Mar 10, 2022

Psyched: First Australian Psych Company On Nasdaq, Utah's Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results

On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval in both Utah chambers, standing out from among dozens of measures currently circulating in legislatures across several U.S. states. Psychedelic science also took an important step forward with the publication…

Benzinga · Mar 7, 2022

Psychedelics And Virtual Reality Treatment Developed By Monash University, Funded By Incannex

Incannex Healthcare Limited (NASDAQ:IXHL) (ASX:IHL) has implemented a license agreement with Monash University to develop a novel treatment that combines virtual reality and psychedelics. This marks the initiation of a second clinical psychedelic therapy program. "We're delighted to have commenced this exciting project and to have expanded our partnership with…

Benzinga · Mar 3, 2022

Read news from The Economist, FT, and more,
with one subscription

Medicinal Cannabis And Psychedelics Company Incannex Lists American Depositary Shares On Nasdaq

Medicinal cannabis and psychedelics company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) commenced trading of its American Depositary Shares representing its ordinary shares on the Nasdaq Global Market under the ticker symbol 'IXHL'.

Benzinga · Feb 28, 2022

Coverage From

Benzinga

People

Alec Baldwin

1,129 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Johns Hopkins University

American Depositary Shares

15 stories

Incannex

11 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.